How to Navigate the FDA’s Guidance on Rare Diseases: A Guide for Biopharma Companies
By Modality SolutionsThe biopharmaceutical industry is at a pivotal moment, particularly those involved in developing drugs for rare diseases.
The recent guidance from the FDA on “Rare Diseases: Considerations for the Development of Drugs and Biological Products” does not signal a paradigm shift in regulatory expectations. However, this guidance extends significantly into biologic drug product manufacturing and cold chain logistics.
To read more, please download this free white paper.